LABELS · b4b42374-17ea-4cc5-8516-3f7731e71bf4

Rybrevant Faspro

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-17
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.2 ) 1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor [see Dosage and Administration (2.2) ]. 1.3 First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.4 Previously Treated NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] , whose disease has progressed on or after platinum-based chemotherapy.

Full extracted label fields

application numbers

BLA761433

boxed warning exact

brand names

Rybrevant Faspro

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e58b045-e352-4f62-99bf-77fae1bebc69

generic names

AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)

b4b42374-17ea-4cc5-8516-3f7731e71bf4

indications and usage exact

1 INDICATIONS AND USAGE RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.2 ) 1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor [see Dosage and Administration (2.2) ]. 1.3 First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.4 Previously Treated NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] , whose disease has progressed on or after platinum-based chemotherapy.

indications and usage tables exact

is original packager

true

manufacturer names

Janssen Biotech, Inc.

matched search terms

cancer

package ndcs

57894-510-01
57894-514-01
57894-515-01
57894-522-01

product ndcs

57894-510
57894-514
57894-515
57894-522

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Dosage and Administration ( 2.1 ) 02/2026 Dosage and Administration ( 2.3 ) 02/2026 Dosage and Administration ( 2.7 ) 02/2026 Dosage and Administration ( 2.8 ) 02/2026 Dosage and Administration ( 2.9 ) 02/2026

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

2729297
2729304
2729306
2729307
2735796
2735797
2735803
2735804

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · unclassified context

application numbers

BLA761433

brand names

Rybrevant Faspro

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 619
end exclusive: true
exact text: 1 INDICATIONS AND USAGE RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution muta
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 0

current approval status

not_reconciled

duplicate text group

dup-75bca3c0a176c9e41476

extraction review status

automated_candidate_pending_source_review

generic names

AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)

ind-span-eb16c4c91ca9f201049b

label id

b4b42374-17ea-4cc5-8516-3f7731e71bf4

positive predicate support span

Source null

qualifier mentions

context exact
combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19
kind
age
polarity
not_inferred
span
end
271
end exclusive
true
exact text
adult patients
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
257
context exact
tion of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combin
kind
biomarker
polarity
not_inferred
span
end
143
end exclusive
true
exact text
MET receptor-directed antibody
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
113
context exact
t-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an
kind
biomarker
polarity
not_inferred
span
end
340
end exclusive
true
exact text
metastatic NSCLC with EGFR exon 19 deletion
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
297
context exact
ertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as de
kind
stage_or_setting
polarity
not_inferred
span
end
328
end exclusive
true
exact text
locally advanced or metastatic NSCLC with EGFR exon
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
277
context exact
ycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
403
end exclusive
true
exact text
first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FD
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
233
context exact
antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
kind
regimen
polarity
not_inferred
span
end
373
end exclusive
true
exact text
in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution m
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
194

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1489
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1455

source span

end: 419
end exclusive: true
exact text: 1 INDICATIONS AND USAGE RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b4b42374-17ea-4cc5-8516-3f7731e71bf4%22

spl effective date

2026-06-17

spl set id

9e58b045-e352-4f62-99bf-77fae1bebc69

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 2 · unclassified context

application numbers

BLA761433

brand names

Rybrevant Faspro

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 916
end exclusive: true
exact text: inib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 220

current approval status

not_reconciled

duplicate text group

dup-d10344b3e362fb886e15

extraction review status

automated_candidate_pending_source_review

generic names

AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)

ind-span-db66a14edf4972386ecb

label id

b4b42374-17ea-4cc5-8516-3f7731e71bf4

positive predicate support span

Source null

qualifier mentions

context exact
nation with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19
kind
age
polarity
not_inferred
span
end
514
end exclusive
true
exact text
adult patients
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
500
context exact
or the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has
kind
biomarker
polarity
not_inferred
span
end
583
end exclusive
true
exact text
metastatic NSCLC with EGFR exon 19 deletion
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
540
context exact
whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.
kind
biomarker
polarity
not_inferred
span
end
715
end exclusive
true
exact text
EGFR tyrosine kinase inhibitor
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
685
context exact
tin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose
kind
stage_or_setting
polarity
not_inferred
span
end
571
end exclusive
true
exact text
locally advanced or metastatic NSCLC with EGFR exon
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
520
context exact
( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after trea
kind
regimen
polarity
not_inferred
span
end
611
end exclusive
true
exact text
in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitut
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
432

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1489
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1455

source span

end: 716
end exclusive: true
exact text: ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 420

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b4b42374-17ea-4cc5-8516-3f7731e71bf4%22

spl effective date

2026-06-17

spl set id

9e58b045-e352-4f62-99bf-77fae1bebc69

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

BLA761433

brand names

Rybrevant Faspro

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1140
end exclusive: true
exact text: th locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease h
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 517

current approval status

not_reconciled

duplicate text group

dup-f99044b18bbf7bbcdf4d

extraction review status

automated_candidate_pending_source_review

generic names

AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)

ind-span-3a0baf33869ac88a6c59

label id

b4b42374-17ea-4cc5-8516-3f7731e71bf4

positive predicate support span

Source null

qualifier mentions

context exact
carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20
kind
age
polarity
not_inferred
span
end
822
end exclusive
true
exact text
adult patients
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
808
context exact
t-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
kind
biomarker
polarity
not_inferred
span
end
891
end exclusive
true
exact text
metastatic NSCLC with EGFR exon 20 insertio
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
848
context exact
etrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test
kind
stage_or_setting
polarity
not_inferred
span
end
879
end exclusive
true
exact text
locally advanced or metastatic NSCLC with EGFR exon
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
828
context exact
.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
939
end exclusive
true
exact text
first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
784
context exact
( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
kind
regimen
polarity
not_inferred
span
end
908
end exclusive
true
exact text
in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as d
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
729

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1489
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1455

source span

end: 940
end exclusive: true
exact text: ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 717

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b4b42374-17ea-4cc5-8516-3f7731e71bf4%22

spl effective date

2026-06-17

spl set id

9e58b045-e352-4f62-99bf-77fae1bebc69

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

BLA761433

brand names

Rybrevant Faspro

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1394
end exclusive: true
exact text: on with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.2 ) 1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line tre
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 741

current approval status

not_reconciled

duplicate text group

dup-0e0e5b5ad2e049a3a300

extraction review status

automated_candidate_pending_source_review

generic names

AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)

ind-span-d6fa69e4a27ef6d6a8d7

label id

b4b42374-17ea-4cc5-8516-3f7731e71bf4

positive predicate support span

Source null

qualifier mentions

context exact
( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20
kind
age
polarity
not_inferred
span
end
1006
end exclusive
true
exact text
adult patients
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
992
context exact
or the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose dise
kind
biomarker
polarity
not_inferred
span
end
1075
end exclusive
true
exact text
metastatic NSCLC with EGFR exon 20 insertio
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1032
context exact
as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test
kind
stage_or_setting
polarity
not_inferred
span
end
1063
end exclusive
true
exact text
locally advanced or metastatic NSCLC with EGFR exon
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1012
context exact
( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemother
kind
regimen
polarity
not_inferred
span
end
1130
end exclusive
true
exact text
as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
953

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1489
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1455

source span

end: 1194
end exclusive: true
exact text: ( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 941

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b4b42374-17ea-4cc5-8516-3f7731e71bf4%22

spl effective date

2026-06-17

spl set id

9e58b045-e352-4f62-99bf-77fae1bebc69

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

BLA761433

brand names

Rybrevant Faspro

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1406
end exclusive: true
exact text: lt patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.2 ) 1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line treatment of ad
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 995

current approval status

not_reconciled

duplicate text group

dup-ef071bb9bcf6147ad758

extraction review status

automated_candidate_pending_source_review

generic names

AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)

ind-span-885f8d0ea760309200dd

label id

b4b42374-17ea-4cc5-8516-3f7731e71bf4

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1489
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1455

source span

end: 1206
end exclusive: true
exact text: ( 1 , 2.2 )
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 1195

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b4b42374-17ea-4cc5-8516-3f7731e71bf4%22

spl effective date

2026-06-17

spl set id

9e58b045-e352-4f62-99bf-77fae1bebc69

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · positive indication candidate

application numbers

BLA761433

brand names

Rybrevant Faspro

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1870
end exclusive: true
exact text: with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.2 ) 1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the treatment of ad
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 1007

current approval status

not_reconciled

duplicate text group

dup-54f38607c5d2a965e7a6

extraction review status

automated_candidate_pending_source_review

generic names

AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)

ind-span-feeb9efb8c914b189591

label id

b4b42374-17ea-4cc5-8516-3f7731e71bf4

positive predicate support span

end: 1371
end exclusive: true
exact text: is indicated
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 1359

qualifier mentions

context exact
th lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung can
kind
age
polarity
not_inferred
span
end
1418
end exclusive
true
exact text
adult patients
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1404
context exact
1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with laz
kind
biomarker
polarity
not_inferred
span
end
1290
end exclusive
true
exact text
EGFR Exon 19 Deletions or Exon 21 L858R Subs
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1246
context exact
t-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 dele
kind
biomarker
polarity
not_inferred
span
end
1487
end exclusive
true
exact text
metastatic non-small cell lung cancer (NSCL
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1444
context exact
lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [se
kind
biomarker
polarity
not_inferred
span
end
1573
end exclusive
true
exact text
EGFR) exon 19 deletions or exon 21 L858R sub
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1529
context exact
dicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)
kind
stage_or_setting
polarity
not_inferred
span
end
1475
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1424
context exact
1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1381
end exclusive
true
exact text
First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the f
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1211
context exact
s or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L8
kind
regimen
polarity
not_inferred
span
end
1506
end exclusive
true
exact text
in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal g
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1327

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1489
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1455

source span

end: 1670
end exclusive: true
exact text: 1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] .
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 1207

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b4b42374-17ea-4cc5-8516-3f7731e71bf4%22

spl effective date

2026-06-17

spl set id

9e58b045-e352-4f62-99bf-77fae1bebc69

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · positive indication candidate

application numbers

BLA761433

brand names

Rybrevant Faspro

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2323
end exclusive: true
exact text: ung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor [see Dosage and Administration (2.2) ]. 1.3 First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the first-line treatment of adult patients w
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 1471

current approval status

not_reconciled

duplicate text group

dup-35631077546b7a125fd9

extraction review status

automated_candidate_pending_source_review

generic names

AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)

ind-span-4c685da0d6e75c5596b8

label id

b4b42374-17ea-4cc5-8516-3f7731e71bf4

positive predicate support span

end: 1846
end exclusive: true
exact text: is indicated
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 1834

qualifier mentions

context exact
rboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19
kind
age
polarity
not_inferred
span
end
1882
end exclusive
true
exact text
adult patients
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1868
context exact
1.2 Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with car
kind
biomarker
polarity
not_inferred
span
end
1749
end exclusive
true
exact text
EGFR Exon 19 Deletions or Exon 21 L858R Subs
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1705
context exact
or the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has
kind
biomarker
polarity
not_inferred
span
end
1951
end exclusive
true
exact text
metastatic NSCLC with EGFR exon 19 deletion
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1908
context exact
whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor [see Dosage and Administration (2.2) ].
kind
biomarker
polarity
not_inferred
span
end
2097
end exclusive
true
exact text
EGFR tyrosine kinase inhibitor [see Dosage a
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2053
context exact
exed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose
kind
stage_or_setting
polarity
not_inferred
span
end
1939
end exclusive
true
exact text
locally advanced or metastatic NSCLC with EGFR exon
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1888
context exact
1.2 Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metas
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1853
end exclusive
true
exact text
Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for th
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1675
context exact
s or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on
kind
regimen
polarity
not_inferred
span
end
1965
end exclusive
true
exact text
in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1786

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1489
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1455

source span

end: 2123
end exclusive: true
exact text: 1.2 Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor [see Dosage and Administration (2.2) ].
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 1671

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b4b42374-17ea-4cc5-8516-3f7731e71bf4%22

spl effective date

2026-06-17

spl set id

9e58b045-e352-4f62-99bf-77fae1bebc69

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 8 · positive indication candidate

application numbers

BLA761433

brand names

Rybrevant Faspro

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2679
end exclusive: true
exact text: with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor [see Dosage and Administration (2.2) ]. 1.3 First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.4 Previously Treated NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with E
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 1924

current approval status

not_reconciled

duplicate text group

dup-9d498a351c8764163e44

extraction review status

automated_candidate_pending_source_review

generic names

AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)

ind-span-e784c28ad08643d15291

label id

b4b42374-17ea-4cc5-8516-3f7731e71bf4

positive predicate support span

end: 2274
end exclusive: true
exact text: is indicated
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 2262

qualifier mentions

context exact
nd pemetrexed, is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20
kind
age
polarity
not_inferred
span
end
2321
end exclusive
true
exact text
adult patients
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2307
context exact
1.3 First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is in
kind
biomarker
polarity
not_inferred
span
end
2207
end exclusive
true
exact text
EGFR Exon 20 Insertion Mutations RYBREVANT F
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2163
context exact
t-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage
kind
biomarker
polarity
not_inferred
span
end
2390
end exclusive
true
exact text
metastatic NSCLC with EGFR exon 20 insertio
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2347
context exact
dicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test
kind
stage_or_setting
polarity
not_inferred
span
end
2378
end exclusive
true
exact text
locally advanced or metastatic NSCLC with EGFR exon
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2327
context exact
1.3 First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the first-line treatment of adult patients with locally advanced or metastatic
kind
prior_therapy_or_line
polarity
not_inferred
span
end
2298
end exclusive
true
exact text
First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the first-line trea
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2128
context exact
CLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage an
kind
regimen
polarity
not_inferred
span
end
2393
end exclusive
true
exact text
in combination with carboplatin and pemetrexed, is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion m
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2214

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1489
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1455

source span

end: 2479
end exclusive: true
exact text: 1.3 First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] .
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 2124

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b4b42374-17ea-4cc5-8516-3f7731e71bf4%22

spl effective date

2026-06-17

spl set id

9e58b045-e352-4f62-99bf-77fae1bebc69

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · positive indication candidate

application numbers

BLA761433

brand names

Rybrevant Faspro

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2858
end exclusive: true
exact text: he first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.4 Previously Treated NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] , whose disease has progressed on or after platinum-based chemotherapy.
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 2280

current approval status

not_reconciled

duplicate text group

dup-9cfbbace47210a9f11db

extraction review status

automated_candidate_pending_source_review

generic names

AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)

ind-span-7e47ed7d062abea9b899

label id

b4b42374-17ea-4cc5-8516-3f7731e71bf4

positive predicate support span

end: 2576
end exclusive: true
exact text: is indicated
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 2564

qualifier mentions

context exact
FASPRO is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20
kind
age
polarity
not_inferred
span
end
2630
end exclusive
true
exact text
adult patients
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2616
context exact
1.4 Previously Treated NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO is indicated as a single agent for the treatment of ad
kind
biomarker
polarity
not_inferred
span
end
2558
end exclusive
true
exact text
EGFR Exon 20 Insertion Mutations RYBREVANT F
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2514
context exact
or the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage
kind
biomarker
polarity
not_inferred
span
end
2699
end exclusive
true
exact text
metastatic NSCLC with EGFR exon 20 insertio
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2656
context exact
as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test
kind
stage_or_setting
polarity
not_inferred
span
end
2687
end exclusive
true
exact text
locally advanced or metastatic NSCLC with EGFR exon
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2636
context exact
1.4 Previously Treated NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detecte
kind
prior_therapy_or_line
polarity
not_inferred
span
end
2662
end exclusive
true
exact text
Previously Treated NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with locally advanced or metast
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2484
context exact
R Exon 20 Insertion Mutations RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] , whose disease has progres
kind
regimen
polarity
not_inferred
span
end
2754
end exclusive
true
exact text
as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see D
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
2577

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

abbreviation
NSCLC
definition exact
non-small cell lung cancer
definition span
end
1489
end exclusive
true
exact text
non-small cell lung cancer (NSCLC)
label id
b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start
1455

source span

end: 2858
end exclusive: true
exact text: 1.4 Previously Treated NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] , whose disease has progressed on or after platinum-based chemotherapy.
label id: b4b42374-17ea-4cc5-8516-3f7731e71bf4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3b01d603f0dc60fbb0ff90774be2260191ce0e40cee7fd963060b8f7c4bec9f7
start: 2480

source url

https://api.fda.gov/drug/label.json?search=id%3A%22b4b42374-17ea-4cc5-8516-3f7731e71bf4%22

spl effective date

2026-06-17

spl set id

9e58b045-e352-4f62-99bf-77fae1bebc69

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice